특발성 폐섬유증 진단 및 치료 시장 : 예측(2025-2030년)

The Idiopathic Pulmonary Fibrosis Diagnostic And Treatment Market is expected to grow from USD 5.917 billion in 2025 to USD 8.549 billion in 2030, at a CAGR of 7.64%.

The Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market Study provides a comprehensive analysis of the global idiopathic pulmonary fibrosis (IPF) diagnostic and treatment market, offering industry experts critical insights into market trends, therapeutic advancements, and competitive strategies shaping this vital healthcare sector. This study explores key market dynamics, including drivers, restraints, and opportunities, with detailed segmentation by type, drug type, route of administration, end-use, and geography. Designed to support strategic decision-making, the Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market Study equips stakeholders with data-driven forecasts, regulatory insights, and competitive intelligence to navigate the evolving landscape of IPF solutions.

Study Overview

The Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market Study examines the global IPF market, segmented by type (Diagnostic Testing, Pharmacological Drugs, Surgical Treatment), drug type (Pirfenidone, Nintedanib, Others), route of administration (Oral, Parenteral), end-use (Hospitals and Clinics, Ambulatory Surgical Centers, Others), and geography (North America, South America, Europe, Middle East and Africa, Asia Pacific). It includes robust analyses such as Porter's Five Forces Analysis, Industry Value Chain Analysis, and market share evaluations, alongside strategic recommendations and regulatory insights to help stakeholders capitalize on growth opportunities in this critical market.

Competitive Environment and Analysis

In the competitive intelligence section of the Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market Study, key players are highlighted for their strategic initiatives to strengthen market presence. For instance, Boehringer Ingelheim has recently advanced its nintedanib portfolio by securing regulatory approvals for expanded indications, enhancing its application in IPF treatment across hospitals and clinics. This development reinforces Boehringer Ingelheim's leadership in pharmacological solutions. Similarly, FibroGen, Inc. has progressed its clinical pipeline through a strategic collaboration to develop novel diagnostic testing methods for early IPF detection, targeting improved patient outcomes in the healthcare sector. The study also covers market share analysis, mergers, acquisitions, and a competitive dashboard to provide a holistic view of the competitive landscape.

Conclusion

The Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market Study is an essential resource for industry experts seeking to understand the complexities of the IPF diagnostic and treatment market. By offering detailed segmentation, technological outlooks, and competitive intelligence, this study provides a robust framework for identifying opportunities and formulating effective strategies. With leading players like Boehringer Ingelheim and FibroGen, Inc. driving innovation in pharmacological and diagnostic advancements, the Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market Study empowers stakeholders to stay competitive in this dynamic and rapidly evolving industry.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2022 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Different segments covered under the idiopathic pulmonary fibrosis diagnostic and treatment market report are as below:

By Type

• Diagnostic Testing
• Pharmacological Drugs
• Surgical Treatment

By Drug Type

• Pirfenidone
• Nintedanib
• Others

By Route of Administration

• Oral
• Parenteral

BY End-Use

• Hospitals and Clinics
• Ambulatory Surgical Centers
• Others

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY TYPE

• 5.1. Introduction
• 5.2. Diagnostic Testing
• 5.3. Pharmacological Drugs
• 5.4. Surgical Treatment

6. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY DRUG TYPE

• 6.1. Introduction
• 6.2. Pirfenidone
• 6.3. Nintedanib
• 6.4. Others

7. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY ROUTE OF ADMINISTRATION

• 7.1. Introduction
• 7.2. Oral
• 7.3. Parenteral

8. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY END-USE

• 8.1. Introduction
• 8.2. Hospitals and Clinics
• 8.3. Ambulatory Surgical Centers
• 8.4. Others

9. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY GEOGRAPHY

• 9.1. Introduction
• 9.2. North America
  • 9.2.1. United States
  • 9.2.2. Canada
  • 9.2.3. Mexico
• 9.3. South America
  • 9.3.1. Brazil
  • 9.3.2. Argentina
  • 9.3.3. Others
• 9.4. Europe
  • 9.4.1. United Kingdom
  • 9.4.2. Germany
  • 9.4.3. France
  • 9.4.4. Spain
  • 9.4.5. Others
• 9.5. Middle East & Africa
  • 9.5.1. Saudi Arabia
  • 9.5.2. Israel
  • 9.5.3. UAE
  • 9.5.4. Others
• 9.6. Asia Pacific
  • 9.6.1. Japan
  • 9.6.2. China
  • 9.6.3. India
  • 9.6.4. South Korea
  • 9.6.5. Indonesia
  • 9.6.6. Thailand
  • 9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 10.1. Major Players and Strategy Analysis
• 10.2. Market Share Analysis
• 10.3. Mergers, Acquisitions, Agreements, and Collaborations
• 10.4. Competitive Dashboard

11. COMPANY PROFILES

• 11.1. Roche Holding AG
• 11.2. Boehringer Ingelheim
• 11.3. AdAlta
• 11.4. FibroGen, Inc.
• 11.5. United Therapeutics
• 11.6. Galecto Biotech

12. APPENDIX

• 12.1. Currency
• 12.2. Assumptions
• 12.3. Base and Forecast Years Timeline
• 12.4. Key benefits for the stakeholders
• 12.5. Research Methodology
• 12.6. Abbreviations